Basic answer is yes I trust LP and nwbo to deliver the goods.
Also, you know nwbo has been a pre-revenue company by definition of developing and trialing its first candidate for approval and sales, so it’s not appropriate to call into question revenues, profits, etc.
Despite this obvious nature of a clinical trial pre revenues stage enterprise, much shareholder value has been created with the IP, manufacturing, completed phase 3 trial that meets primary and secondary endpoints representing a breakthrough for treating GBM and rGBM, and soon to be approved, with current market cap around $800M-$1B next surging into the multi billions!